DSP 9632 P
Alternative Names: DSP-9632PLatest Information Update: 24 Aug 2023
At a glance
- Originator Sumitomo Dainippon Pharma
- Developer Sumitomo Pharma
- Class Antiparkinsonians
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Drug-induced dyskinesia
Most Recent Events
- 02 Dec 2022 Sumitomo Pharma completes phase-I trial in Drug-induced dyskinesias (In adults, In the elderly) in Japan (Transdermal) (NCT05435729)
- 31 May 2022 Phase-I clinical trials in Drug-induced dyskinesias (In adults, In the elderly) in Japan (Transdermal) (NCT05435729)
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma